Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab
Not yet recruitingOBSERVATIONAL
Enrollment
20
Participants
Timeline
Start Date
July 1, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
Conditions
Third-line TreatmentDvanced Duodenal AdenocarcinomaFurquinelone Combined With Sintilimab
Interventions
DRUG
furquimatinib and sintilimab
furquimatinib and sintilimab
All Listed Sponsors
lead
RenJi Hospital
OTHER
NCT05810142 - Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab | Biotech Hunter | Biotech Hunter